The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
S100A2 as a prognostic marker in patients receiving adjuvant therapy for pancreatic cancer (PC): A secondary analysis of RTOG 9704.
M. A. Tempero
No relevant relationships to disclose
K. A. Winter
No relevant relationships to disclose
G. E. Kim
No relevant relationships to disclose
S. Kakar
No relevant relationships to disclose
T. S. Hyun
No relevant relationships to disclose
W. Regine
No relevant relationships to disclose
R. B. Mowat
No relevant relationships to disclose
K. Charpentier
No relevant relationships to disclose
W. Small
No relevant relationships to disclose
C. Guha
No relevant relationships to disclose
D. K. Chang
No relevant relationships to disclose
A. V. Biankin
No relevant relationships to disclose